Take the tablet whole with water. It can be taken with or without food. Do not crush, chew, or split the tablet.

Lasgrain acts as a selective agonist for 5-hydroxytryptamine1B and 5-hydroxytryptamine1D (5-HT1B/1D) receptors on cranial blood vessels and nerve endings. This action leads to vasoconstriction of intracranial blood vessels, which are dilated during a migraine attack, and inhibits the release of pro-inflammatory neuropeptides from trigeminal nerve endings, thereby aborting a migraine attack.

• •History of ischemic heart disease (angina pectoris, myocardial infarction).
• •Uncontrolled hypertension.
• •History of stroke or transient ischemic attack (TIA).
• •Peripheral vascular disease.
• •Severe hepatic impairment.
• •Concomitant use with ergotamine-containing or ergot-type medications.
• •Concomitant use with other 5-HT1 agonists (triptans).
• •Hypersensitivity to the active substance or any excipients.

Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.

In case of overdose, symptoms may include severe dizziness, drowsiness, vomiting, and cardiovascular events. Treatment should be symptomatic and supportive, including monitoring of ECG and blood pressure. There is no specific antidote.

Pregnancy Category C. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is unknown whether Lasgrain is excreted in human milk; use with caution in breastfeeding mothers.